Finch - Model CP101 - Microbiome Therapeutics for Chronic Hepatitis B (HBV)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and complications including cirrhosis, liver failure requiring liver transplantation, liver cancer, and death.
The Unmet Need
>290 million people globally have chronic HBV, with approximately 30 million individuals becoming newly infected every year
900,000 deaths globally from chronic HBV-related complications per year
Currently available treatment options are poorly tolerated and ineffective for many chronic HBV patients, with active replication and elevated viral loads persisting after treatment
There is a need for safe and effective therapies that drive toward a functional cure for the millions of people suffering from chronic HBV
CP101 for Chronic HBV
Oral delivery of a lyophilized, intact microbiome community harvested from rigorously screened healthy, human donors
Designed to facilitate viral clearance by delivering an intact microbiome community that stimulates the immune system
Development program leverages mechanistic data and several investigator-sponsored, proof-of-concept clinical studies showing viral antigen clearance following microbiota transplantation